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Inverse association between serum 
bilirubin level and testosterone 
deficiency in middle‑aged and older 
men
Hye‑Min Park 1,2, Haeyoung Kim 3, Hye Sun Lee4 & Yong‑Jae Lee 5*
Low serum bilirubin levels have been associated with increased risk of cardiovascular disease (CVD) 
and metabolic syndrome. Testosterone deficiency could also contribute to increased risk of CVD and 
metabolic syndrome. Therefore, this study aimed to examine the relationship between serum bilirubin 
level and testosterone deficiency in 1284 Korean men aged 45 to 70 years. Serum bilirubin level 
was categorized into quartiles: Q1 ≤ 0.7, Q2 0.8–0.9, Q3 1.0–1.1, and Q4 ≥ 1.2 mg/dL. Testosterone 
deficiency was defined as level less than 8.0 nmol/L, as suggested by the position statement of 
International Society of Andrology. The overall prevalence of testosterone deficiency was 5.8% and 
significantly decreased with the quartiles from Q1 to Q4. Compared with the referent fourth quartile 
(serum bilirubin ≥ 1.2 mg/dL), the ORs (95% CIs) for testosterone deficiency was 2.29 (1.04–4.94) for 
the first quartile after adjusting for age, fasting glucose, triglyceride, HDL‑cholesterol, leukocyte 
count, hemoglobin, smoking status, and alcohol intake. We found inversely graded associations of 
serum bilirubin level with testosterone deficiency. These findings suggest that low bilirubin level may 
be interpreted as a state of testosterone deficiency in middle‑aged and older men.
Testosterone level in men is well documented to remain stable until around 40 years of age and then to decline 
at about 1% per year as a natural result of  aging1. Male hypogonadism is a condition in middle-aged and older 
men characterized by low testosterone level with clinical symptoms including sexual dysfunction, depressed 
mood, lack of muscle mass, abdominal obesity, and deteriorated quality of  life2,3. Approximately 2–6% of men 
aged over 65 years will have symptoms of  hypogonadism4. Accumulating epidemiological evidence shows that 
testosterone deficiency contributes to increase risk of metabolic syndrome and cardiovascular disease (CVD)5, 
which are highly linked to chronic low-grade inflammation. Hence, early identification of individuals at higher 
risk for testosterone deficiency is important for male health and quality of life.
Bilirubin is made from biliverdin by the work through heme oxygenase and biliverdin reductase and is an 
end product of heme  catabolism6. Serum bilirubin level has been regarded as an indicator of hepatobiliary 
dysfunction or  hemolysis7, but all the evidence that has piled up suggests that bilirubin is a potent antioxidant 
and endogenous cytoprotective agent in the progress of cardiometabolic  diseases8. Previous studies show that 
low level of serum bilirubin is relevant to increased risk of metabolic syndrome, carotid atherosclerosis, and 
coronary artery  disease9–11.
Since low levels of both testosterone and bilirubin are associated with elevated risk of cardiometabolic dis-
eases, we inferred a possible association between testosterone levels and serum bilirubin. Therefore, this study 
aimed to examine the relationship between serum bilirubin level and testosterone deficiency in 1284 Korean 
men aged 45–70 years.
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Methods
Study population. We reviewed the medical records of 1401 participants aged ≥ 45 years retrospectively 
who had a medical examination between November 2012 and July 2013 at the Health Promotion Center of 
Gangnam Severance Hospital in Seoul, Korea. The individuals visited the health promotion center willingly 
to regularly check their health condition. Written informed consent was obtained from all participants. This 
study was authorized by the Institutional Review Board of Yonsei University College of Medicine, Seoul, Korea 
(approval No. 3-2019-0319) and was managed in according to the ethical principles of the Declaration of Hel-
sinki. We excluded men who met at least one of the following criteria: individuals with a history of hepatobil-
iary disease, positive test for hepatitis C antigens or hepatitis B antibodies, a history of exogenous testosterone 
therapy, above twice the upper normal limit for aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT), total bilirubin levels of more than 3.0 mg/dL, hemoglobin level of less than 13 g/dL, not fasting for 12 h 
before testing or missing data. After applying the exclusion criteria, the final analysis included 1284 participants.
Data collection. Each participant was asked to fill in a questionnaire about his medical history and life-
style. Self-reported alcohol consumption, physical activity, and cigarette smoking were determined from the 
questionnaires. Smoking status was classified as current smoker, ex-smoker, and non-smoker. Alcohol drinking 
was assessed into consumption ≥ twice a week. Regular exercise was considered as more than 30 min of aerobic 
exercise ≥ three times a week. Body mass and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, 
in light indoor clothing without shoes. Body mass index (BMI) was calculated as weight in kilograms divided 
by square of height in meters (kg/m2). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
measured using a standard mercury sphygmomanometer (Baumanometer, W.A. Baum Co Inc., Copiague, NY, 
USA) and the patient’s right arm. After a 12-h overnight fast, all blood samples were taken from the antecubital 
vein. Testosterone concentrations were determined using an electrochemiluminescence assay with a Modular 
Analytics E170 system (Roche Diagnostic Systems, Basel, Switzerland). The reproducibility was determined by 
calculating the intra- and inter-assay coefficients of variation (CV) as follow: [% CV = (SD/mean) * 100]. For 
intra-assay CV, the same serum was assayed three times in duplicate within the same assay. The inter-assay 
reproducibility was assessed by analyzing six times the consecutive assays in  duplicate12. The intra-assay and 
inter-assay CVs for testosterone were 3.2% and 3.3%, respectively. Fasting glucose, triglycerides, high density 
lipoprotein (HDL) cholesterol, AST, ALT, and total bilirubin were quantified with enzymatic methods using a 
chemistry analyzer (Hitachi 7600, Hitachi Co., Tokyo, Japan). Leukocyte count was measured using an auto-
mated blood cell counter (ADVIA 120, Bayer, NY, USA).
Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or 
current use of hypertension  medication13. Type 2 diabetes was defined as current use of diabetes medication or 
fasting plasma glucose ≥ 126 mg/dL14. Dyslipidemia was set as triglyceride ≥ 150 mg/dL, HDL-cholesterol < 40 mg/
dL, or use of dyslipidemia medications at present. The modified National Cholesterol Education Program Adult 
Treatment Panel III (NCEP-ATP III) released in 2001 was applied to designate metabolic  syndrome15. According 
to the position statement of the American College of Endocrinology, we defined obesity as BMI ≥ 25 kg/m2, since 
waist circumference was not  measured16. Thus, metabolic syndrome was defined by the existence of three or more 
of risk factors as follows: obesity with BMI ≥ 25 kg/m2, elevated fasting plasma glucose ≥ 126 mg/dL or current 
use of diabetes medication, high systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, anti-
hypertensive drugs, low HDL cholesterol < 40 mg/ dL and high triglycerides ≥ 150 mg/dL.
Statistical analysis. Normal distribution was assessed with determination of skewness by Kolmogorov–
Smirnov test. ALT, AST, serum triglyceride levels had skewed distributions, therefore these variables were indi-
cated as median with interquartile range (IQR) in descriptive analysis and log-transformed preceding to simple 
correlation and multiple logistic regression analysis. Serum bilirubin level was divided into quartiles: Q1 ≤ 0.7, 
Q2 0.8–0.9, Q3 1.0–1.1, and Q4 ≥ 1.2  mg/dL. The clinical characteristics of the study population according 
to serum bilirubin quartile were independently compared using one-way analysis of variance (ANOVA) or 
Kruskal–Wallis test for continuous variables in accordance with the normality of distributions and chi-square 
test for categorical variables. Continuous data are exhibited as mean (standard deviation [SD]) or median (IQR), 
and categorical data are marked as frequency. Testosterone deficiency was defined as level less than 8.0 nmol/L, 
as proposed by the announcement of the International Society of Andrology (ISA)17,18. The odds ratios (ORs) 
and 95% confidence intervals (95% CIs) for testosterone deficiency were calculated after adjusting for confound-
ing variables over serum bilirubin quartiles using multiple logistic regression analysis. We have included the 
confounding variables in the logistic regression analysis model considering the commonly performed statisti-
cal principles to include clinically established important risk factors and statistically significant variables in the 
simple regression analysis. All analyses were carried out using SAS statistical software (version 9.4; SAS Institute 
Inc., Cary, NC, USA). All statistical tests were two-sided, and statistical significance was determined at P < 0.05.
Informed consent. Informed consent was obtained from all the participants in the current study.
Results
Table1 shows the clinical characteristics of the study population according to serum bilirubin quartiles. Leuko-
cyte count and fasting plasma glucose level were lowest, while HDL- cholesterol level was highest in the fourth 
quartile of bilirubin concentration. The proportions of current smoking was highest in the first quartile of serum 
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Figure 1 presents the prevalence of subjects with testosterone deficiency in each bilirubin quartile. The overall 
prevalence of testosterone deficiency was 5.8% and significantly decreased in accordance with serum bilirubin 
quartile (Q1 8.1%, Q2 7.0%, Q3 4.9%, and Q4 3.3%) (P = 0.026).
Table 2 indicates the results of multiple logistic regression analysis to assess the association between serum 
bilirubin level and testosterone deficiency. Compared with the referent fourth quartile (serum bilirubin ≥ 1.2 mg/
Table 1.  Clinical characteristics of the study population according to serum bilirubin quartiles. BP blood 
pressure, HDL high density lipoprotein, NA not applicable. Data are expressed as the mean (SD), median 
(IQR), or percentage. P-values were calculated using 1-way ANOVA test, Kruskal–Wallis test, or chi-square 
test. The differences of mean, median and proportion between groups were determined using post hoc 
analysis of ANOVA, Kruskal–Wallis test and chi-squared test using Bonferroni corrections. a Q1 versus Q2, 
bQ1 versus Q3, cQ1 versus Q4, dQ2 versus Q3, eQ2 versus Q4, fQ3 versus Q4, gAlcohol drinking ≥ twice/week. 
hRegular exercise ≥ three times/week. iHypertension was defined as a systolic blood pressure ≥ 140 mmHg, 
diastolic blood pressure ≥ 90 mmHg, or the current use of hypertension medication. jType 2 diabetes was 
defined as a fasting plasma glucose ≥ 126 mg/dL or the current use of diabetes medication. kDyslipidemia was 
defined as triglyceride ≥ 150 mg/dL or HDL-cholesterol < 40 mg/dL for men or the current use of dyslipidemia 
medications.
Serum bilirubin quartiles (mg/dL)
Q1 (≤ 0.7) Q2 (0.8–0.9) Q3 (1.0–1.1) Q4 (≥ 1.2) P value Post hoc
n 275 356 302 351
Age (years) 57.3 (8.1) 56.4 (7.3) 54.7 (7.1) 55.2 (7.3) 0.001 b,c,d
Body mass index (kg/m2) 24.9 (2.6) 24.6 (2.5) 24.6 (2.5) 24.4 (2.5) 0.197
Systolic BP (mmHg) 126.4 (15.0) 127.3 (15.2) 127.2 (17.0) 127.4 (16.8) 0.859
Diastolic BP (mmHg) 78.9 (8.9) 79.6 (8.7) 80.2 (9.8) 79.8 (9.6) 0.339
Mean arterial pressure (mmHg) 94.7 (10.4) 95.6 (10.3) 95.9 (11.5) 95.7 (11.5) 0.577
Hemoglobin (g/dL) 15.0 (0.9) 15.1 (1.0) 15.4 (1.1) 15.6 (1.0)  < 0.001 b,c,d,e
Hematocrit (%) 44.2 (2.6) 44.5 (2.8) 45.0 (3.1) 45.3 (3.0)  < 0.001 b,c,e
Fasting glucose (mg/dL) 105.6 (27.0) 102.8 (23.3) 100.6 (22.3) 99.5 (17.1) 0.006 b,c,
Triglyceride (mg/dL) 127 (93–175) 113 (81–158) 112 (85–169) 109 (80–149) 0.014 c
HDL-cholesterol (mg/dL) 44.0 (10.9) 47.1 (11.2) 47.4 (11.6) 48.4 (10.8)  < 0.001 a,b,c
Aspartate aminotransferase (U/L) 22 (18–26) 22 (19–26) 22 (18–27) 22 (19–26) 0.963
Alanine aminotransferase (U/L) 23 (18–32) 23 (19–32) 24 (18–33) 22 (18–30) 0.703
Leukocyte (cells/μL) 6590 (1740) 6217 (1801) 6019 (1571) 5984 (1674)  < 0.001 a,b,c
Current smoking (%) 43.6 31.7 28.7 22.1  < 0.001 b,c,d
Alcohol drinking (%)g 45.6 52.2 53.5 44.5 0.053
Regular exercise (%)h 40.5 43.1 42.8 45.8 0.632
Hypertension (%)i 45.5 46.9 43.4 40.5 0.348
Type 2 diabetes (%)j 17.8 14.6 11.1 10.9 0.042 c
Dyslipidemia (%)k 35.6 30.4 28.8 24.4 0.024 c
Metabolic syndrome (%) 40.3 36.8 32.1 30.2  < 0.001 b,c
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dL), the ORs (95% CIs) for testosterone deficiency was 2.29 (1.04–4.94) for the first quartile after adjusting for age, 
fasting glucose, triglyceride, HDL-cholesterol, leukocyte count, hemoglobin, smoking status, and alcohol intake.
Discussion
In this cross-sectional study, serum bilirubin level was independently and inversely associated with testosterone 
deficiency in a dose–response way after adjusting for potential confounding variables. To date, it has been rarely 
investigated on the association between serum bilirubin level and testosterone deficiency. The plausible explana-
tions may be offered to explain the inverse relationship between serum bilirubin level and testosterone deficiency.
First, low levels of testosterone and bilirubin are closely interrelated to oxidative stress and chronic low-grade 
inflammation. In our study, serum bilirubin level was inversely associated with leukocyte count, a nonspecific 
marker of systemic inflammation. Hwang et al. also reported that CRP level decreased with increasing bilirubin 
quartiles among apparently healthy  adults19. Both animal and human studies have documented that bilirubin 
could serve as a potent lipid chain-breaking antioxidant under physiological concentrations, inhibiting the for-
mation of atherogenic  plaques20,21. Given the antioxidant capacity of bilirubin, epidemiological links between 
low serum bilirubin level and increased risk for atherosclerotic CVD and the severity of CAD have been shown 
in cross-sectional and longitudinal  studies22. Among 4303 participants aged ≥ 60 years in the NHANES, a low 
total bilirubin level of 0.1–0.4 mg/dL was associated with higher mortality  risk23. English et al. found statisti-
cally significant lower levels of testosterone in patients with catheterization-proven CAD compared with control 
 groups24. In addition, mildly elevated unconjugated bilirubin reduces the risk of CVD in individuals with Gilbert’s 
 syndrome25. Likewise, extended evidence also implies that chronic low-grade inflammation is closely involved 
in the pathogenesis of male  hypogonadism26. Pro-inflammatory cytokines such as tumor necrosis factor-α and 
interleukin-6 are released from adipose tissues in testosterone deficiency, which leads to a subclinical inflamma-
tory  condition27. A recent study suggests that low testosterone levels may be interpreted as a state of low-grade 
inflammation. Park et al. revealed an inverse associations of testosterone levels with leukocyte counts in Korean 
 adults26.
Second, low levels of testosterone and bilirubin are closely related to insulin resistance and metabolic 
 abnormalities28,29. Recent epidemiological studies have shown that there is an inverse association of serum bili-
rubin and testosterone levels with cardiometabolic disturbances, such as obesity, hypertension, type 2 diabetes, 
and metabolic syndrome. In a prospective study of 468 Taiwanese middle-aged men, a higher bilirubin level 
was associated with a reduced future risk of metabolic syndrome particularly in nonsmoking  men30. Our study 
also found a significant difference in the prevalence of type 2 diabetes, dyslipidemia, and metabolic syndrome 
according to serum bilirubin quartiles. A low testosterone level could be a result of insulin resistance through 
increasing visceral adiposity and decreasing skeletal  muscle31. Low testosterone also increases lipoprotein lipase 
activity, leading to increase triglyceride uptake in central fat  depots32, insulin resistance and metabolic syndrome. 
Thus, increased abdominal visceral fat and low testosterone levels have bidirectional interactions. Previous stud-
ies have demonstrated that hypercholesterolemia, glycemic control, visceral adiposity and insulin resistance in 
hypogonadal men with type 2 diabetes or metabolic syndrome were improved through testosterone replacement 
 therapy33,34. Aslo, Wickramatilake et al. showed a positive association of testosterone with HDL-cholesterol level 
in angiographically confirmed CAD in  men35.
This study had some limitations to its interpretation. First, we used a cross-sectional design and were not 
able to prove a causal relationship between serum bilirubin and testosterone deficiency. The results may mirror 
reverse causality and a bidirectional relationship in the association between these variables. Therefore, further 
large-scale with a long follow-up period, prospective studies are warranted to establish whether there is a cause-
and-effect relationship between serum bilirubin and testosterone deficiency. Second, the study population might 
not represent the general population because the study participants were volunteers visiting a single health 
promotion center to screen their health condition and seemed to be a little bit healthier than most community-
based cohorts. Third, only one measurement of bilirubin and testosterone levels from a baseline examination 
was included in the analyses. Fourth, the definition of type 2 diabetes does not meet the criteria of American 
Diabetes Association, since any information about HbA1c and 2-h plasma glucose levels were not collected from 
the dataset. Finally, the cut-off point for testosterone deficiency in the present study was defined as < 8.0 nmol/L 
as proposed by the announcement of the ISA. Men with levels between 8–12 nmol/L also may be testosterone 
deficiency, however testosterone deficiency symptoms and free testosterone levels should also be considered in 
this range of serum total testosterone. Unfortunately, we could not collect further information on testosterone 
deficiency symptoms and free testosterone levels from the initial dataset.
Table 2.  Odds ratios and 95% confidence for testosterone deficiency according to serum bilirubin quartiles. 
a Adjusted for age. b Adjusted for age, fasting plasma glucose, and triglyceride. c Adjusted for age, fasting plasma 
glucose, triglyceride, HDL-cholesterol, leukocyte count, hemoglobin, smoking status, and alcohol intake.
Serum bilirubin quartiles (mg/dL)
Q1 (≤ 0.7) Q2 (0.8–0.9) Q3 (1.0–1.1) Q4 (≥ 1.2)
Model  1a 2.15 (1.07-4.92) 1.99 (0.92-4.52) 1.27 (0.60-2.67) 1.00
Model  2b 2.23 (1.06-4.98) 1.98 (0.95-4.50) 1.24 (0.59-2.64) 1.00
Model  3c 2.29 (1.04-4.94) 1.99 (0.94-4.39) 1.32 (0.73-3.60) 1.00
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In conclusion, we found an inversely graded association of serum bilirubin level with testosterone deficiency. 
In conclusion, we found an inversely graded association of serum bilirubin level with testosterone deficiency and 
CVD risk factors. These findings suggest that low serum bilirubin level may be assumed as a state of testosterone 
deficiency and CVD risk in middle-aged and older men.
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